Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | GUSB | P08236 | 2/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.36 |
| ▸ | LSS | P48449 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19780199 | 1.00 | DPP4 (0.37) | DPP4GUSBSPHK2SPHK1GNAI3 | |
| SCHEMBL23491200 | 1.00 | DPP4 (0.37) | DPP4GUSBSPHK2SPHK1GNAI3 | |
| SCHEMBL19779643 | 1.00 | DPP4 (0.37) | DPP4GUSBSPHK2SPHK1GNAI3 | |
| SCHEMBL19880475 | 0.86 | DPP4 (0.36) | DPP4GUSBSPHK2SPHK1GNAI3 | |
| SCHEMBL22962308 | 0.85 | GUSB (0.40) | GUSBSPHK2SPHK1GBA1 | |
| SCHEMBL22962306 | 0.85 | GUSB (0.40) | GUSBSPHK2SPHK1GBA1 | |
| SCHEMBL22096780 | 0.81 | GNAI3 (0.39) | DPP4SPHK2SPHK1GNAI3GNAO1 | |
| SCHEMBL19779599 | 0.81 | GNAI3 (0.39) | DPP4SPHK2SPHK1GNAI3GNAO1 | |
| SCHEMBL19780154 | 0.81 | GNAI3 (0.39) | DPP4SPHK2SPHK1GNAI3GNAO1 | |
| SCHEMBL19880406 | 0.81 | GNAI3 (0.39) | DPP4SPHK2SPHK1GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-06-10 | — | — | US | disclosed |
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
| US-10351547-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190002431-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2019-01-03 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | DPP4 95/4885GUSB 1523/4885SPHK2 368/4885 |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | DPP4 95/4885GUSB 1523/4885SPHK2 368/4885 |
| US-10351547-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | DPP4 95/4885GUSB 1523/4885SPHK2 368/4885 |
| US-20190002431-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | DPP4 95/4885GUSB 1523/4885SPHK2 368/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | DPP4 95/4885GUSB 1523/4885SPHK2 368/4885 |
| US-20210171492-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | DPP4 95/4885GUSB 1523/4885SPHK2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.